Arrowhead (ARWR) announced a $25M milestone payment from Amgen (AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran. Arrowhead is further eligible to receive up to an additional $535M in aggregate development, regulatory, and sales milestone payments from Amgen and Royalty Pharma (RPRX).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARWR:
- Piper recommends ‘down market cap’ biotech exposure for 2023
- Piper Sandler names three top biotechnology picks for 2023
- Horizon Therapeutics announces first subject does in HZN-457 trial
- Arrowhead price target lowered to $90 from $110 at H.C. Wainwright
- Arrowhead price target lowered to $59 from $65 at B. Riley